AZD-5363

Product ID A9601

Cas No. 1143532-39-1

Purity ≥99%, ≥99%ee

Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description
Product Info
Shipping and Storage
Downloads
References
Custom Order

Description

AZD-5363 is an oral pan-AKT inhibitor that causes hyperphosphorylation of AKT, locking it in a catalytically inactive state, unable to phosphorylate downstream signaling substrates such as PRAS40 and GSK-β. This compound displays anticancer chemotherapeutic activity, inhibiting proliferation and inducing tumor regression in in vitro and in vivo models of HER2+ breast cancer and prostate cancer. AZD-5363 may also exhibit inhibitory activity against Rho-associated protein kinase (ROCK), p70S6K, PKA, MKK1, MSK1, MSK2, PKC, PKG, PRKX, and RSK2/3.

Product Info

Cas No.	1143532-39-1
Purity	≥99%, ≥99%ee
Formula	C₂₁H₂₅ClN₆O₂
Formula Wt.	428.92
IUPAC Name	4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)piperidine-4-carboxamide
Synonym	AZD5363
Solubility	In DMSO(86mg/ml), water with 2 eq. of acid, insoulble on ethanol
Appearance	White Crystal Powder

Shipping and Storage

Store Temp	-20°C
Ship Temp	Ambient

Downloads

MSDS	A9601 MSDS PDF
Info Sheet	A9601 Info Sheet PDF
Brochures	PI3K-Akt-mTORC Pathway Booklet

References

Addie M, Ballard P, Buttar D, et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem. 2013 Mar 14;56(5):2059-73. PMID: 23394218.

Lamoureux F, Thomas C, Crafter C, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013 Feb 15;19(4):833-44. PMID: 23258740.

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.